International Narcotics Control Board
الهيئة الدولية لمراقبة المخدرات (Arabic)

国际麻醉品管制局 (Chinese)
Organe International de Contrôle des Stupéfiants (French)
Международный Комитет по Контролю над Наркотиками (Russian)

Junta Internacional de Fiscalización de Estupefacientes (Spanish)
PredecessorPermanent Central Opium Board and Drug Supervisory Board
Formation1968; 56 years ago (1968)
Founded atGeneva, Switzerland
TypeTreaty body
Legal statusActive
PurposeTreaty body of the 1961 Convention, 1971 Convention, and 1988 Convention
HeadquartersVienna International Centre (Vienna, Austria)
13 Board Members
Jallal Toufiq
Mark Colhoun
Main organ

The International Narcotics Control Board (INCB) is an independent treaty body, one of the four treaty-mandated bodies under international drug control law (alongside the Commission on Narcotic Drugs, UNODC on behalf of the Secretary-General, and the WHO).[1]

The INCB is responsible for monitoring the control of substances pursuant to the three United Nations drug control conventions and for assisting Member States in their efforts to implement those conventions.[2] It plays an important role in monitoring the production and trade of narcotics and psychotropics, as well as their availability for medical and scientific purposes, and in deciding which precursors should be regulated.[3]


The Board has predecessors since the League of Nations. Following the 1909 Shanghai International Opium Commission, an International Opium Convention was adopted in 1925 and established the Permanent Central Opium Board (PCOB) which started its work in 1928. Later on, the 1931 Convention created the Drug Supervisory Body to gather estimates, in complement of the PCOB.[4][5]

After the dissolution of the League of Nations in 1946, the Lake Success Protocol Amending the Agreements, Conventions and Protocols on Narcotic Drugs transferred the powers and mandate of both Permanent Central Opium Board and Drug Supervisory Board to a specially-created joint body to administer the estimate system. The functions of both bodies were merged into the current INCB in 1961 with the adoption of the Single Convention on Narcotic Drugs, but the INCB only started its work in 1968 when the Single Convention entered into force.

Initially, the composition of the INCB under the Single Convention was strongly influenced by the 1946 Protocol. It inherited mechanisms of nomination from the League of Nations and Office International d'Hygiène Publique.

The mandates and functions of the INCB were later complemented with the adoption of the Convention on Psychotropic Substances in 1971 and the UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances in 1988.

Comparison of the role of the INCB with its predecessors within the organisational structure of international drug control[6]
Organisational chart of inter-governmental drug control (as of 1935) Organisational chart of inter-governmental drug control (as of 2022)

Treaty mandates

The drug control treaties mandates four international bodies: the Board, the World Health Organization, the Secretary-General of the United Nations (nowadays represented by the United Nations Office on Drugs and Crime), and the Commission on Narcotic Drugs. The commission has power to influence drug control policy by advising other bodies and deciding how various substances will be controlled. Enforcement power lies in the mandate of each State Party to the Conventions. The Board has mostly a monitoring and surveillance role.

Responsibilities under the 1961 and 1971 Conventions

The INCB has a role generally similar under the 1961 and 1971 Conventions. The substances under scrutiny differ.

The 1961 Single Convention, Article 9 provides that the Board shall endeavour to:

But these refer to monitoring and advice, rather than enforcement. The INCB has no direct enforcement powers.

Articles 12 and 19[2] of the same Convention give the Board the responsibility of reviewing, confirming, or requesting changes to the annual estimates of needs for narcotic drugs among Parties concerning licit cultivation, production, manufacture, export, import, distribution and trade, with the objective of preventing diversion of drugs from licit sources into the illicit traffic. The estimates do not represent quotas in the strict sense, because the Parties may at any time request changes to their annual estimates, subject to providing the Board with the explanation of the circumstances necessitating such changes. The Board establishes estimates for all nations, including non-Parties to the Single Convention.

Under the 1971 Convention on Psychotropic Substances, similar powers are given to the Board, in regards to psychotropic substances. In addition, Article 18 of the 1971 Convention requires the Board to issue annual reports on its work.

Lack of direct enforcement powers and "quasi-judicial" mandate

During the negotiations of the Single Convention, governments refused to give the INCB direct enforcement powers.[4] Article 14 of the Single Convention, Article 19 of the 1971 Convention, and Article 22 of the 1988 Convention, give the Board the authority to investigate the failure of any country or region to carry out the convention's provisions. This includes countries that are not Parties to the Conventions. The Board can ask for explanations from the Government in question, propose that a study of the matter be carried out in its territory, and call upon the Government to adopt remedial measures.

If the Board finds that the Government has failed to give satisfactory explanations, or has failed to adopt remedial measures that it has been called upon to take, the Board can call the attention of the Parties, the council, and the commission to the matter. The Board can also publish a report on the matter for communication to all Parties. Under some circumstances, it can penalize a violator by reducing its export quota of opium, under the provisions of Article 21 bis.[2] The Board can even "recommend to the Parties that they stop the export, import, or both, of particular psychotropic substances, from or to the country or region concerned, either for a designated period or until the Board shall be satisfied as to the situation in that country or region."

The Commentary to the Convention on Narcotic Drugs points out, "This is a very serious measure, and it cannot be assumed that the Board has that authority except in very grave situations".[7] Decisions under Article 19 require a two-thirds vote of the Board.

INCB has been criticized for claiming being a "quasi-judicial" body whereas neither the three drug control Conventions nor ECOSOC resolutions provide it with such a mandate. In September 2022, Virginia Patton Prugh, Attorney Advisor at the United States Department of State, declared on the occasion of an intersessional meeting of the Commission on Narcotic Drugs:[8]

Reviewing the many sources discussing INCB mandates, one would assume that the INCB has been designated to sit in judgement of MS in their effort to implement the treaties. If that it the case, it must be found in the treaties. But the treaties do not assign this role: it simply isn't there. The INCB is authorized to administer the system of estimates and the statistical returns, and to support the Parties in implementing the Conventions. But there is no text suggesting that the INCB is given quasi-judicial functions to interpret the treaties, or adjudicate their conformity or compliance. Read the text; look carefully at the words: we, the Parties to the Conventions, are responsible for implementing our obligations, and we are also responsible for interpreting them in good faith.

The position that the INCB is not and should not self-define as a "quasi-judicial" body had been defended by civil society organisations[9] and scholars[10][11][12] for a number of years.

Responsibilities under the 1988 Convention

Article 12[2] of the 1988 Convention Against Illicit Traffic requires the Board to report annually to the Commission on Narcotic Drugs on the implementation of the convention's restrictions on chemical precursors in Table I and Table II, the treaty's two categories of precursor substances in illicit drug manufacture. The INCB "Red List" lists precursors and chemicals frequently used in illicitly manufacturing narcotics and psychotropic substances under international control.[13]

In the case of a precursor substance not yet regulated, the convention also requires the Board to communicate to the Commission on Narcotic Drugs an assessment of the substance if it finds that:

The Convention requires the Board to notify the United Nations Secretary-General whenever it has information which, in its opinion, may justify adding a substance to, deleting a substance from, or transferring a substance between, the Tables. The Secretary-General then transmits that information to the Parties and the commission, and the Commission makes the decision, "taking into account the comments submitted by the Parties and the comments and recommendations of the Board, whose assessment shall be determinative as to scientific matters, and also taking into due consideration any other relevant factors".

This role of assessment given to the INCB under the 1988 Convention was, under the 1961 and 1971 Convention, was reserved to the World Health Organization.

Notably, this Convention explicitly preludes the INCB from playing any role in the settlement of disputes between two or more Parties relating to the interpretation or application of the convention, instead leaving the resolution of these disputes to the Parties concerned through peaceful means of their own choice.

Responsibilities under ECOSOC resolutions

This section is empty. You can help by adding to it. (December 2022)


Membership of the Board

Article 9 of the Single Convention specifies that the Board shall be made up of thirteen members elected by the UN Economic and Social Council (ECOSOC), including:[2]

The Article requires the council to make arrangements to ensure the Board's independence. Article 10[2] specifies that "[t]he members of the Board shall serve for a period of five years, and may be re-elected."

The lengthy terms, and the fact that the Board is made up of individuals rather than nation-states, help buffer the Board from political pressure. Historians have argued that the requirement that members with "medical, pharmacological or pharmaceutical experience" be placed on the Board was the result of lobbying by the pharmaceuticals industry.[4]

The provision that three members would be WHO nominees is similar to provision in previous treaties, which had two of the four members of the Drug Supervisory Body to be appointed by the Office International d'Hygiène Publique (OIHP), the predecessor of WHO. The requirement that INCB nominees be appointed by ECOSOC in the Single Convention is inherited from the previous treaty provision.[6]


Board Members elect a president among them for a one-year term.


Although the 13 Members of the Board are independent, the Secretariat, officers, and staff of the INCB are entrusted to the United Nations. States parties to the 1961 Convention already expressed their desire to see INCB Secretariat integrated within the United Nations system under Secretary-General:[14]

That secretariat is an integral part of the Secretariat of the United Nations; while under the full administrative control of the Secretary-General, it is bound to carry out the decisions of the Board; The members of the secretariat are appointed or assigned by the Secretary-General; the head of that secretariat is appointed or assigned in consultation with the Board.

The Commentary to the Convention on Psychotropic Substances notes, "Since the Board is not in continuous session and in fact meets only a few weeks each year, it has to delegate to its secretariat the required authority in order to maintain between its sessions 'the mechanism for a continuing dialogue' with Governments".[15] Additionally, in 1990, the Board noted that "by decision of the Secretary-General, the Director-General of the United Nations Office at Vienna serves as Coordinator of all United Nations drug control-related activities."[16] Resolution 1991/46 of the United Nations Economic and Social Council entrusted the management of INCB Secretariat to the agency known today as United Nations Office on Drugs and Crime.

Historical list of INCB Presidents, Members, and Secretaries[3][17]
Year Secretary President Member No. 1 Member No. 2 Member No. 3 Member No. 4 Member No. 5 Member No. 6 Member No. 7 Member No. 8 Member No. 9 Member No. 10 Member No. 11 Member No. 12 Member No. 13
1968 Joseph Dittert Sir Harry Greenfield[18]
Paul Reuter[16]
Stefan Stepczyński Molsen Kchouk (Tunisia)
1979 Abdelaziz Bahi
1983 Victorio V. Olguin
1985 Betty C. Gough Zhi-Ji Cai (China)
1987 Sahibzada Raoof Ali Khan Sirad Atmodjo (Indonesia)
Ben Huyghe-Braeckmans
1990 Liselotte Waldheim-Natural Betty C. Gough[16] Huascar Caiias Kauffmann (Bolivia) Marith Vasudev Narajan Rao (India) Oskar Schroeder (Austria) General Mohamed Mansour (Egypt)
1991 Herbert Schaepe Oskar Schroeder
1992 Salubzada Raoof Ali Khan


Dr. Manuel Quijano-Narezo


Gottfried Machata (Austria) Hamid Ghodse (Iran) Dr. Bunsom Martin


Amb. Herbert S. Okun


1993 Hamid Ghodse
1995 Oskar Schroeder Prof. Alfredo Pemjean


António Lourenço Martins (Portugal)
Edoward A. Babasan


Dil Jan Khan (Pakistan) Elba Torres Graterol (Venezuela)
1997 Hamid Ghodse
Nelia Cortes-Maramba (Philippines) Jacques Franquet


Alfonso Gómez-Méndez(Colombia)
1998 Chinmay Chakrabarty(India)
1999 Antonio Lourenço Martins Sergio Uribe Ramirez (Colombia)
2000 Hamid Ghodse
Nüzhet Kandemir (Turkey) Philip Onagwele Emafo (Nigeria) Prof. Jiwang Zheng


Maria Elena Medina-Mora (Mexico)
2002 Philip Onagwele Emafo Elisaldo Luiz de Arajo Carlini (Brazil)
Madan Mohan Bhatnagar


Rainer Wolfgang Schmid (Austria) Robert Jean Joseph Chretien Lousberg (Netherlands) Rosa Maria del Castillo Rosas


Amb. Melvyn Levitsky


2004 Koli Kouame (Ivory Coast) Hamid Ghodse Gilberto Gerra (Italy)
Tatyana Borisovna Dmitrieva


Joseph Bediako Asare


Sevil Atasoy


Dr. Camilo Uribe Granja (Colombia)
2006 Philip Onagwele Emafo Major Brian Watters (Australia)
Sri Suryawati (Indonesia) Carola Lander (Germany) Prof. Xin Yu


2008 Hamid Ghodse Raymond Yans (Belgium)
2009 Sevil Atasoy
2010 Jonathan Lucas (Seychelles) Hamid Ghodse
2011 Andres Finguerut (UK)
2012 Raymond Yans
Amb. David T. Johnson (US)
2014 Lochan Naidoo
2015 Werner Sipp Jagjit Pavadia (India) Jallal Toufiq (Morocco) Bernard Leroy (France) Richard P. Mattick (Australia)
2017 Viroj Sumyai Galina A. Korchagina (Russia) Luis A. Otárola Peñaranda (Peru) Raúl Martín Del Campo Sánchez (Mexico) Sevil Atasoy (Turkey) Cornelis P. de Joncheere (Netherlands)
2019 Cornelis P. de Joncheere
2020 Stefano Berterame(Italy) Viviana Manrique Zuluaga (Colombia) Cesar T. Arce Rivas (Paraguay) Prof. Zukiswa Zingela

(South Africa)

2021 Mark Colhoun (South Africa) Jagjit Pavadia
2022 Richard Muscat


2023 N. Larissa Razanadimby (Madagascar) Lin Lu (China) Pavel Pachta (Czechia)
Jallal Toufiq Pierre Lapaque (France) Mariângela Batista Galvão Simão (Brazil)

Global Projects

International Import and Export Authorization System (I2ES)

The International Import and Export Authorization System (I2ES)[19] is an international import and export authorization system that uses an online platform developed in 2015 by the International Narcotic Control Board (INCB) with the support of the United Nations Office on Drugs and Crime (UNODC). I2ES is an online platform developed to facilitate and speed up the process of issuing import and export authorizations for narcotic drugs and psychotropic substances by competent national authorities (CNAs) of importing and exporting countries in compliance with the international drug control treaties. I2ES will allow CNAs to verify the authenticity of such authorizations and to issue endorsements of export authorizations in a secure way and in real time.

INCB Learning

Launched in 2016, INCB Learning[20] is one of the Board's initiatives to assist Member States in implementing the recommendations of the UNGASS outcome document[21] and the INCB Availability Report (2015).[22] INCB Learning addresses the barriers to adequate availability of indispensable narcotic and psychotropic substances required for medical treatments, particularly by raising awareness and providing training.

Global OPIOIDS Project

The Board recognized early on that the alarming increase in overdose deaths from non-medical synthetic opioids threatened to become a global challenge. In response, the Board initiated its global Operational Partnerships to Interdict Opioids' Illicit Distribution and Sales (OPIOIDS) Project.[23] The OPIOIDS Project is the only current international effort solely dedicated to developing partnerships with governments, international agencies and the private sector to share information and intelligence with the goal of identifying and interdicting illicit manufacturers, distributors and vendors of synthetic opioids.

The OPIOIDS Project supports national authorities and international organizations' efforts in preventing nonmedical synthetic opioids and fentanyl-related substances from reaching people, by:

Project ION - International Operations on New Psychoactive Substances (NPS)

Project ION (International Operations on NPS)[24] is the operational initiative of INCB, supporting national authorities' efforts in preventing non-scheduled new psychoactive substances (NPS) of abuse from reaching consumer markets.

Project ION activities are primarily engaged in the coordination, collection and communication of strategic and operational information related to suspicious shipments of, trafficking in, or manufacture or production of NPS. A specific focus is on synthetic NPS with little or no known medical, scientific or industrial uses and our activities are primarily engaged in the coordination, collection and communication of strategic and operational information.

Public-Private Partnerships

In recent years, voluntary public-private partnerships[25] have come to play an increasingly important role in global precursor control. In this context, the concept aims at preventing the diversion of chemicals for illicit purposes, through cooperation between national authorities and the private sector. INCB has further expanded its public-private partnerships to include legitimate e-commerce and B2B operators, marketing and social media, online financial service providers, and express mail and courier services. These voluntary partnerships supplement the obligatory controls prescribed by the 1988 Convention against Illicit Traffic.


Lack of "quasi-judicial" powers

The INCB routinely defines itself as a "quasi-judicial" body.[1] The position that the INCB is not a "quasi-judicial" body had been defended by governments,[8] civil society organisations,[9][26] and scholars[10][11][12] for a number of years.

INCB criticism of domestic policy reforms

The Board routinely draws the attention of the international community to interesting drug control developments. However, the INCB has been criticised for their behaviour in urging sovereign states to stay in bounds of the conventions, on the grounds that it may not be within INCB's mandate to comment on matters that are the sole purview of national governments.[26] The move to a more political role combined with a very rigid interpretation of the drug control conventions, passing judgement on states, is considered problematic.[27]

In April 2003, former UNODC Chief of Demand Reduction Cindy Fazey penned a scathing review of the Board, accusing it of overstepping its bounds:[28]

Unfortunately these individuals also see their role not only as the guardians of the conventions, but also the interpreters of them as well. In their annual report they have criticised many governments, such as Canada for permitting the medicinal use of cannabis, Australia for providing injecting rooms and the United Kingdom for proposing to downgrade the classification of cannabis, which would entail less serious penalties than at present. These criticisms go far beyond their remit, and indeed it is hubris to criticise the Canadian Supreme Court.

Criticism of UK cannabis rescheduling

On the United Kingdom, the report of the Board for 2002 noted "the announcement by the Government of the United Kingdom that cannabis would be placed in a different schedule, requiring less severe controls, and the worldwide repercussions caused by that announcement, including confusion and widespread misunderstanding. A survey undertaken in the United Kingdom found that as many as 94 per cent of children believed that cannabis was a legal substance or even some type of medicine. The survey also discovered that nearly 80 per cent of teachers in the United Kingdom believed that the recent reclassification of cannabis would make educating pupils about the dangers of drug abuse more challenging and difficult. Several opinion polls taken in July and August 2002 found that the majority of the population did not support that reclassification." (Paragraph 499[29]) Parliamentary Under Secretary of State Bob Ainsworth responded:[30]

The comments made in your report, your selective and inaccurate use of statistics, and failure to refer to the scientific basis on which the UK Government's decision was based all add up to an ill-informed and potentially damaging message. This was compounded by the way in which the Board presented the cannabis reclassification decision to the media at the launch of its annual report on 26 February. For example, the Board representative is quoted as having said that we might end up in the next 10 or 20 years with our psychiatric hospitals filled with people who have problems with cannabis, and that a recent study by the British Lung Foundation found smoking three cannabis joints caused the same damage to the linings of the airways as 20 cigarettes. These are totally misleading statements.

In 2008, the Home Secretary of the United Kingdom recommended that cannabis be reclassified as a class B drug.[31]

Position on personal cultivation of cannabis

In 2005, in the wake of the United States Supreme Court's decision in Gonzales v. Raich, the Board welcomed "the decision of the United States Supreme Court, made on 6 June, reaffirming that the cultivation and use of cannabis, even if it is for 'medical' use, should be prohibited." The Board's president, Hamid Ghodse, opined:[32]

INCB has for many years pointed out that the evidence that cannabis might be useful as a medicine is insufficient. Countries should not authorise the use of cannabis as a medicine until conclusive results based on research are available. Sound scientific evidence for its safety, efficacy and usefulness is required to justify its use in medical practice. Any research into cannabis as a medicine should involve the World Health Organization, as the responsible international health agency.

INCB's rejection of the right to cultivate cannabis for personal purposes has been deemed to lack substantial justification.[11][12]

In 2020, the INCB launched an "Cannabis Control Initiative"[33][34][35] which was also criticized for failing to acknowledge the tension between its approach to cannabis control and the right to privacy, recognized in international human rights law and by the Constitutional Courts of a number of countries""[12][9]

Criticism of the legalization of cannabis in Uruguay and Canada

In 2013, then-President of the Board Raymond Yans reportedly labeled Uruguay as a "pirate country" because of its decision to regulate cannabis for recreational purposes. Similar criticism was expressed when Canada followed suit in 2018.[36][37]

In 2019, a month after the World Health Organization recommended to lower the scheduling status of cannabis and cannabis resin, the INCB reiterated its interpretation that laws and policies allowing for the recreational use of cannabis are "contrary to the international drug control treaties."[38]

Access and availability of controlled drugs for medical use

The INCB has published several special reports on the availability of opiates for medical needs, going back to 1989 and 1995[39] and has repeatedly called for urgent global action to address the situation.[40] In its 2008 report, noting that millions of people around the world are suffering from acute and chronic pain, the INCB calls on governments to support a new programme of the World Health Organization (WHO), which aims at improving access to those medicines.[41] But a number of civil society stakeholders, such as the Senlis Council, has argued that the INCB is not taking seriously its responsibility vis-à-vis the global needs for medicines:[42]

The INCB is responsible for ensuring adequate supplies of drugs for medical use. Currently millions of people are suffering due to a mounting global shortage of opium-based painkillers such as morphine and codeine, especially in the developing world. The methods used by the INCB to calculate the amounts needed of these medicines are flawed and need to be reconsidered.

A 2020 research found that "for fifty years, the INCB has focussed predominantly upon [...] illicit uses, with little attention to [...] therapeutic Uses. Decreasing attention is provided to the estimates of annual requirements system, under which global opioid access to opioids is documented as inadequate."[43]

Human rights and transparency

In 2019, observers noted that in "recent years have seen the Board, through its annual report, become progressively more engaged with the issue of human rights."[44] But issues remain open.[45][11] In December 2021, a group of 181 non-governmental organizations wrote to the Secretary-General of the United Nations to express concerns about the need for human rights due diligence in the work of the Board related to cannabis.[35][9]

Opacity of the proceedings

Many observers and stakeholders have criticized the lack of transparency, accountability, and mechanisms for participation in INCB work, contrary to other United Nations system entities.[46] In 2010, a report of the London School of Economics noted, "INCB remains perhaps the most closed and least transparent of any entity supported by the United Nations. There are no minutes or public reports on the deliberations of the INCB. The INCB's proceedings are closed not only to NGOs but also to member states."[10]

The report noted the United Nations Security Council had transparency, accountability and participation mechanisms that are more open than those of the INCB.

Observers noted that as of December 2021, the situation had not improved.[9][47]

See also


  1. ^ a b INCB (2022). "Mandate and functions". Archived from the original on 11 December 2022. Retrieved 11 December 2022.
  2. ^ a b c d e f UNODC, Secretariat to the Governing Bodies, Division for Treaty Affairs (2013). The International Drug Control Conventions: Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol; Convention on Psychotropic Substances of 1971; United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988; with final acts and resolutions (PDF). Vienna: United Nations. Archived (PDF) from the original on 5 December 2021. Retrieved 23 January 2022.((cite book)): CS1 maint: multiple names: authors list (link)
  3. ^ a b Ghodse, Hamid (2008). International drug control into the 21st century. Substance Abuse Librarians and Information Specialists (SALIS). Aldershot : Ashgate. pp. 10–11. ISBN 978-0-7546-7215-9.
  4. ^ a b c McAllister, William B. (2000). Drug Diplomacy in the Twentieth Century – An international history. New-York: Routledge. ISBN 978-1-134-68065-8. Archived from the original on 20 December 2022. Retrieved 24 January 2022.
  5. ^ Renborg, B. A. (1957). International Control of Narcotics. Law and Contemporary Problems, 22(1 Narcotics), 86–112. Archived 28 February 2022 at the Wayback Machine
  6. ^ a b Riboulet-Zemouli; Krawitz; Ghehiouèche (2022). "Cannabis amnesia – Indian hemp parley at the Office International d'Hygiène Publique in 1935". Authorea Preprints. doi:10.22541/au.165237542.24089054/v1 (inactive 31 January 2024). Archived from the original on 18 May 2022. Retrieved 11 December 2022.((cite web)): CS1 maint: DOI inactive as of January 2024 (link)
  7. ^ United Nations (1973). Commentary on the Single Convention on Narcotic Drugs of 1961 + Commentary on the 1972 Amendment.
  8. ^ a b Private recording of the Intersessional meeting of the United Nations Commission on Narcotic Drugs including Thematic Discussions on the Implementation of all International Drug Policy Commitments, following up to the Ministerial Declaration of 2019, held 21–22 September 2022 in Vienna, Austria. Program
  9. ^ a b c d e "Open Letter addressed to United Nations Secretary-General António Guterres and copied to UNODC Executive Director Ghada Fathi Waly, regarding the need for transparency and accountability within the International Narcotics Control Board (INCB), particularly in relation to the "INCB Cannabis Control Initiative.'". Statement submitted by Fields of Green for All NPC, a non-governmental organization in special consultative status with the Economic and Social Council. Commission on Narcotic Drugs, Reconvened sixty-fourth session; Vienna, 9 and 10 December 2021; Agenda item 5(c), Implementation of the international drug control treaties: International Narcotics Control Board [E/CN.7/2021/NGO/7]. Vienna: United Nations. 2021. Archived from the original on 23 January 2022. Retrieved 23 January 2022.
  10. ^ a b c Governing the Global Drug Wars – Special Report SR014 – October 2012 (PDF). London: LSE ideas. 2012. Archived (PDF) from the original on 19 January 2022. Retrieved 23 January 2022.
  11. ^ a b c d Bewley-Taylor, David (2019). The International Narcotics Control Board on cannabis: A critique of the report for 2018 (PDF). London: International Drug Policy Consortium. Archived (PDF) from the original on 22 January 2022. Retrieved 24 January 2022.
  12. ^ a b c d Riboulet-Zemouli, Kenzi; Krawitz, Michael A. (24 February 2021). "Voluntary Contribution to INCB Guidelines on Medical Cannabis – Due Diligence, Good Faith, & Technical Concerns". Rochester, NY. SSRN 3829901. ((cite journal)): Cite journal requires |journal= (help)
  13. ^ "List of Precursors and chemicals Frequently used in the illicit manufacture of narcotic drugs and psychotropic substances under International Control" (PDF). January 2020. Archived (PDF) from the original on 8 April 2023. Retrieved 28 July 2023.
  14. ^ United Nations Conference to consider amendments to the Single Convention on Narcotic Drugs, 1961 (1972). "Resolution I "Secretariat of the International Narcotics Control Board"; Resolutions adopted by the United Nations Conference to consider amendments to the Single Convention on Narcotic Drugs, 1961.". The International Drug Control Conventions. Part One: Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol (PDF). Geneva: United Nations. p. 19. Archived (PDF) from the original on 5 December 2021. Retrieved 23 January 2022.((cite book)): CS1 maint: numeric names: authors list (link)
  15. ^ Article 2 – Amendments to the Title of Article 9 of the Single Convention and Its Paragraph 1 and Insertion of New Paragraphs 4 and 5 Archived 2004-12-21 at the Wayback Machine
  16. ^ a b c INCB (1990). Report of the International Narcotics Control Board for 1990 [E/INCB/1990/1; United Nations Publication Sales No. E.90.XI.3] (PDF). New-York: United Nations. ISBN 92-1-148082-5. Archived (PDF) from the original on 9 August 2021. Retrieved 23 January 2022.
  17. ^ INCB (2022). "INCB Membership". Archived from the original on 11 December 2022. Retrieved 11 December 2022.
  18. ^ "UNODC - Bulletin on Narcotics - 1968 Issue 2 - 007". United Nations : Office on Drugs and Crime. Archived from the original on 23 January 2022. Retrieved 23 January 2022.
  19. ^ "I2ES - International Import Export System". Archived from the original on 10 December 2021. Retrieved 10 December 2021.
  20. ^ "INCB Learning Global Programme". Archived from the original on 10 December 2021. Retrieved 10 December 2021.
  21. ^ Archived 2 August 2019 at the Wayback Machine [bare URL PDF]
  22. ^ Archived 30 January 2020 at the Wayback Machine [bare URL PDF]
  23. ^ INCB. "OPIOIDS project". Archived from the original on 10 December 2021. Retrieved 10 December 2021.
  24. ^ INCB. "Project ION". Archived from the original on 10 December 2021. Retrieved 10 December 2021.
  25. ^ "Public-Private Partnerships". Archived from the original on 10 December 2021. Retrieved 10 December 2021.
  26. ^ a b International Drug Policy Consortium (2010). "Advocacy Note - A Call to the New Secretary of the International Narcotics Control Board: Ongoing Challenges". IDPC. Rochester, NY. SSRN 1909986 – via SSRN. ((cite journal)): |last= has generic name (help)
  27. ^ "The UN Drug Control Conventions". 8 October 2015. Archived from the original on 3 February 2018. Retrieved 3 December 2015.
  28. ^ " - aprile 2003". Archived from the original on 23 April 2015. Retrieved 29 October 2011.
  29. ^ "Archived copy" (PDF). Archived from the original (PDF) on 17 November 2008. Retrieved 11 January 2022.((cite web)): CS1 maint: archived copy as title (link)
  30. ^ "Road to Vienna: British Government Chides International Narcotics Control Board on Cannabis Rescheduling Critique". Archived from the original on 22 November 2008. Retrieved 11 March 2005.
  31. ^ "Cannabis classification | Home Office". 27 October 2008. Archived from the original on 27 October 2008.
  32. ^ "INCB: US Supreme Court Decision on Cannabis Upholds International Law". Archived from the original on 14 May 2011.
  33. ^ "INCB holds Expert Group Meeting on control and monitoring requirements of cannabis and cannabis-related substances". Archived from the original on 24 January 2022. Retrieved 24 January 2022.
  34. ^ "INCB discusses supply of cannabis raw material and demand for cannabinoids with regulatory agencies, industry and international organizations". Archived from the original on 24 January 2022. Retrieved 24 January 2022.
  35. ^ a b "'The World Needs A Cannabis Initiative That Serves Citizens. Not One That Serves A Decadent International Bureaucracy'". BusinessCann. 10 August 2021. Archived from the original on 23 January 2022. Retrieved 23 January 2022.
  36. ^ "ONU: La legalización de la marihuana en Uruguay es una actitud de 'piratas'". La Vanguardia (in Spanish). 12 December 2013. Archived from the original on 24 January 2022. Retrieved 24 January 2022.
  37. ^ Walsh, John; Jelsma, Martin (29 November 2019). "Regulating Drugs: Resolving Conflicts with the UN Drug Control Treaty System". Journal of Illicit Economies and Development. 1 (3): 266–271. doi:10.31389/jied.23. ISSN 2516-7227. S2CID 214167735.
  38. ^ "INCB: Medical cannabis programs violate international drug control treaties". MJBizDaily. 5 March 2019. Archived from the original on 24 January 2022. Retrieved 24 January 2022.
  39. ^ INCB. "Report of the International Narcotics Control Board for 1995: Availability of Opiates for Medical Needs" (PDF). Archived from the original (PDF) on 24 May 2010. Retrieved 11 January 2022.
  40. ^ "U.N. Agency: Global Action Needed to Improve Opioid Availability". 21 August 2008. Archived from the original on 21 August 2008.
  41. ^ INCB (2008). "Press Release No. 4 - Annual report: Ensuring Access to Pain Treatment Medicines Is Vital and Possible, Says INCB" (PDF). Archived from the original (PDF) on 16 November 2008. Retrieved 11 January 2022.
  42. ^ Senlis Council (2008). "Failing international drug control system: Think tank warns of grave consequences of global dimensions – Current drug policy is endangering world security and hindering development". Archived from the original on 22 November 2007. Retrieved 16 April 2007.
  43. ^ Clark, Joseph D.; Johnson, Miriam; Fabowale, Blessing; Farrelly, Michael; Currow, David (29 May 2020). "Does the International Narcotics Control Board (INCB) sufficiently prioritise enablement of access to therapeutic opioids? A systematic critical analysis of six INCB annual reports, 1968-2018". Journal of Global Health Reports. 4: e2020042. doi:10.29392/001c.12925. S2CID 219755704. Archived from the original on 23 January 2022. Retrieved 23 January 2022.
  44. ^ "The International Narcotics Control Board on human rights: A critique of the report for 2019". Archived from the original on 23 January 2022. Retrieved 23 January 2022.
  45. ^ Fordham, Ann (1 September 2020). "The Meaningful Participation of 'Stakeholders' in Global Drug Policy Debates—A Policy Comment". International Development Policy | Revue internationale de politique de développement (12). doi:10.4000/poldev.3861. ISSN 1663-9375. S2CID 225196865. Archived from the original on 24 January 2022. Retrieved 24 January 2022.
  46. ^ Fordham, Ann (27 August 2020). The Meaningful Participation of 'Stakeholders' in Global Drug Policy Debates—a Policy Comment. Brill Nijhoff. pp. 153–171. doi:10.1163/9789004440494_010. ISBN 978-90-04-44049-4. Archived from the original on 24 January 2022. Retrieved 24 January 2022.
  47. ^ "Documenting the INCB Cannabis Control Initiative". Kenzi Riboulet-Zemouli. Archived from the original on 14 February 2022. Retrieved 13 February 2022.

Official links:

Civil society monitoring pages: